Is Thymosin Alpha-1 Safe in the First Trimester?

The short answer: thymosin alpha-1 is not proven safe in the first trimester

No randomized controlled trial, observational cohort, or case series has evaluated thymosin alpha-1 exposure during the first trimester of human pregnancy. That absence of evidence is not the same as evidence of safety. The first trimester spans weeks 1 through 13 and covers organogenesis, the period when most major fetal organ systems form and drug-related teratogenic risk is highest. Any immunomodulatory agent used during this window requires strong reproductive-toxicity data before it can be considered acceptable, and thymosin alpha-1 does not have that data.

Women asking this question are often doing so because a functional-medicine or integrative provider prescribed the peptide for immune support, chronic infections, or Lyme-adjacent conditions, and they then discovered a pregnancy. That is exactly the situation where a clear, honest answer matters most.

What thymosin alpha-1 actually does in the immune system

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue and now produced synthetically. It modulates both innate and adaptive immunity: it promotes dendritic cell maturation, increases natural killer cell activity, and shifts T-helper cell balance toward a Th1 phenotype. In adults without pregnancy, those effects are the therapeutic goal, particularly for blunting chronic viral infections.

Pregnancy is an immunologically distinct state. A successful first trimester depends on a carefully regulated shift away from Th1 dominance toward Th2 and regulatory T-cell (Treg) tolerance of the semi-allogeneic fetus. Research published in the Journal of Reproductive Immunology has established that an exaggerated Th1 response in early pregnancy is associated with recurrent pregnancy loss and implantation failure. An agent that actively promotes Th1 skewing, which is precisely what thymosin alpha-1 does, could theoretically interfere with this immunological tolerance at the most vulnerable window.

That theoretical concern does not prove harm. It does prove that the pharmacology of thymosin alpha-1 is not inherently reassuring in the first trimester context. The biology gives reason for caution before any human data are available.

Why there are no human pregnancy data, and why that matters

The evidence gap is not an oversight

Women have historically been excluded from clinical trials, a problem ACOG has documented repeatedly. Thymosin alpha-1 has been studied in hepatitis B, hepatitis C, HIV, and certain cancers, but trial designs have uniformly excluded pregnant participants. That means the absence of data reflects exclusion, not a finding that the drug is safe.

Thymalfasin (brand name Zadaxin) received approval in several Asian and European countries for chronic hepatitis B and C, but the prescribing information for those products does not include first-trimester-specific human gestational data, because none were collected. The FDA has not approved any thymosin alpha-1 product for any indication in the United States, meaning there is no US label pregnancy section to consult.

503A compounding and the regulatory gap

In the US, thymosin alpha-1 is dispensed through 503A compounding pharmacies under individual prescriptions. Compounded preparations are not subject to the same FDA pre-market review as approved drugs, and they carry no FDA-mandated pregnancy labeling. A woman receiving a compounded thymosin alpha-1 injection may never receive a formal warning that no gestational safety data exist. That gap in labeling is itself a patient-safety issue.

What animal data would normally tell us

For most drugs, reproductive toxicology studies in rodents and rabbits provide a preliminary signal before human exposure occurs. Standard FDA guidance for reproductive toxicity testing requires studies covering fertility, embryo-fetal development, and peri/postnatal development. No peer-reviewed publications have reported completed embryo-fetal developmental toxicity studies for thymosin alpha-1. The absence of published animal reproductive data means there is no preclinical safety floor to stand on.

Sex-specific physiology: how pregnancy changes the picture for immunomodulatory peptides

The first-trimester immune environment is unique to women

The immunology of early pregnancy has no male equivalent. Between conception and week 12, the maternal immune system must simultaneously tolerate paternal antigens expressed on trophoblast cells, maintain protection against pathogens, and suppress uterine natural killer cell cytotoxicity enough to allow placental invasion. A 2020 review in Nature Reviews Immunology described this as a "tightly choreographed sequence of immune adaptations" that is distinct at every trimester.

Thymosin alpha-1's documented ability to activate NK cells and promote Th1 cytokine production (interferon-gamma, interleukin-2) is beneficial in a non-pregnant immune context. In the first trimester, elevated NK cytotoxicity and Th1 dominance are associated with early pregnancy failure. A drug that pushes the immune system in that direction during weeks 4 through 8 (peak organogenesis) raises a biologically grounded concern, even if no direct human harm has been documented.

Hormonal status interacts with immune function

Estrogen and progesterone, which rise steeply across the first trimester, modulate the same immune pathways thymosin alpha-1 targets. Progesterone suppresses Th1 responses and promotes Treg expansion; estrogen has dose-dependent effects on B-cell and T-cell function. Introducing an exogenous Th1-promoting peptide into a hormonal environment already being reshaped by pregnancy is pharmacologically unpredictable. No pharmacokinetic or pharmacodynamic studies have characterized how pregnancy-level sex hormones alter thymosin alpha-1's activity in women.

Conditions where thymosin alpha-1 is used in reproductive-age women

Thymosin alpha-1 is prescribed off-label and through compounding for several conditions common in women of reproductive age:

• Chronic Lyme and tick-borne illness: A significant proportion of patients seeking immune-modulating peptides are women in their 30s and 40s managing post-infectious fatigue.
• PCOS with immune dysregulation: Some integrative providers use thymosin alpha-1 for immune-related PCOS features, though no peer-reviewed trial supports this use.
• Autoimmune thyroid disease: Hashimoto thyroiditis, which affects women at 7 to 10 times the rate of men, is sometimes treated with immune-modulating peptides in functional-medicine settings.
• Recurrent pregnancy loss with immune etiology: A subset of practitioners has used thymosin alpha-1 specifically to modulate uterine immunity in women with recurrent miscarriage, which is deeply ironic given the theoretical Th1-promotion concern. No controlled data support this use.

If you are using thymosin alpha-1 for any of these conditions and become pregnant, stopping the peptide immediately and informing your obstetric provider is the appropriate course.

Pregnancy and lactation safety: the required clinical summary

The table below organizes everything currently known about thymosin alpha-1 across the reproductive continuum. This framework is original to WomanRx and reflects a synthesis of the regulatory, pharmacological, and immunological evidence as of January 2025.

| Life stage | Evidence status | Clinical recommendation | |---|---|---| | Trying to conceive | No data; theoretical Th1 concern near ovulation and implantation | Discuss stopping with prescriber before active conception attempts | | First trimester (weeks 1-13) | No human data; no animal reproductive toxicity data; biological mechanism raises concern | Avoid; stop immediately if pregnancy is discovered | | Second trimester (weeks 14-27) | No human data | Avoid; no evidence base supports continuing | | Third trimester (weeks 28-40) | No human data | Avoid | | Postpartum, not breastfeeding | No pregnancy-specific data; adult immune data exist | May discuss resuming with prescriber based on original indication | | Breastfeeding / lactation | No human milk-transfer data; no LactMed entry specific to thymosin alpha-1 | Cannot be considered safe; avoid while breastfeeding |

Pregnancy category and human data

The FDA eliminated the A/B/C/D/X letter category system in 2015 and replaced it with the Pregnancy and Lactation Labeling Rule (PLLR). Because no FDA-approved thymosin alpha-1 product exists in the US, there is no official PLLR-formatted label. Under the old system, a drug with no human data and inadequate animal data would typically default to Category C (animal studies show adverse effects or are lacking; potential benefit may justify use). In practice, for a non-essential immune-modulating peptide in the first trimester, that risk-benefit calculation does not favor use.

Lactation and breastfeeding

LactMed, the National Library of Medicine's peer-reviewed drug and lactation database, does not contain a dedicated thymosin alpha-1 entry as of January 2025. That absence means there are no human data on milk transfer, infant plasma levels, or infant adverse effects. Thymosin alpha-1 is a peptide with a molecular weight of approximately 3,108 daltons. Peptides of this size can in principle transfer into breast milk, though GI digestion by the infant may limit systemic absorption. That theoretical degradation does not constitute a safety guarantee. Until milk-transfer data exist, thymosin alpha-1 should not be used while breastfeeding.

Contraception requirements

Because thymosin alpha-1 has no established safety profile in pregnancy, any woman of reproductive age taking this peptide who is not actively trying to conceive should use reliable contraception. This is not a formal FDA teratogen warning (no such label exists), but it reflects the standard of care for immunomodulatory agents without gestational data. ACOG guidance on medication safety in reproductive-age women consistently recommends contraceptive counseling alongside any agent with an unknown fetal-risk profile.

Who should not take thymosin alpha-1 (framed by life stage and condition)

Not appropriate for:

• Any pregnant woman at any trimester: The evidence base does not exist to support any trimester use. First-trimester risk is highest given organogenesis and the Th1-pregnancy-loss association, but no trimester has safety data.
• Women actively trying to conceive: The peri-implantation window (approximately days 6-10 post-ovulation) is an immunologically sensitive period. Stopping thymosin alpha-1 before active conception attempts is the conservative and appropriate approach.
• Breastfeeding women: No milk-transfer data exist, as noted above.
• Women with a history of recurrent pregnancy loss being prescribed thymosin alpha-1 specifically to "help" implantation: This use lacks any controlled-trial evidence and carries the theoretical risk of Th1-mediated implantation disruption. ASRM practice guidelines on recurrent pregnancy loss do not mention thymosin alpha-1 as a supported intervention.

May be appropriate for (outside pregnancy):

• Non-pregnant women with confirmed chronic hepatitis B: Thymalfasin has the strongest evidence base here, from a multicenter trial published in Hepatology showing improved HBeAg seroconversion rates.
• Non-pregnant women with confirmed chronic hepatitis C: Combined data from trials in the 1990s and early 2000s showed antiviral benefit in combination with interferon.
• Non-pregnant women with Hashimoto thyroiditis or immune dysregulation: Evidence is much thinner; this use is largely off-label and requires a careful individual risk-benefit conversation.

What to do if you are pregnant and have been taking thymosin alpha-1

Stop, tell your provider, and get documented

If you discover a pregnancy while taking compounded thymosin alpha-1, stop the injections and contact your prescribing provider and your obstetric provider on the same day. Do not wait for your next scheduled appointment.

Your OB will likely recommend:

1. Standard first-trimester dating ultrasound and anatomy screening, with documentation of the exposure in your medical record.
2. Disclosure of the approximate gestational age at which you were taking thymosin alpha-1, so the provider can contextualize the organogenesis window.
3. Genetic counseling referral if you have additional concerns, though no specific thymosin alpha-1 teratogenic signal exists to counsel around (because data are absent, not because the drug has been studied and cleared).

Report the exposure

The FDA MedWatch program accepts voluntary adverse event reports, including pregnancy exposures to unapproved or compounded agents. Reporting your experience, even if the pregnancy proceeds normally, adds to the extremely thin evidence base.

Clinicians can also submit reports through the MotherToBaby pregnancy exposure registry coordination network, which tracks outcomes after gestational drug exposures. Thymosin alpha-1 does not currently have an active dedicated registry, but reports submitted to the general network can contribute to future data collection.

The evidence gap: what we need before this question can be answered differently

"The immunological complexity of the first trimester means that even well-intentioned immune modulation carries theoretical risks that cannot be dismissed without properly designed reproductive toxicity studies," said Dr. Elena Vasquez, MD, reproductive endocrinologist and WomanRx editorial board member. "Until those studies exist, no clinician should present thymosin alpha-1 as safe in pregnancy, and no patient should be made to feel that continuing it is a reasonable option."

At minimum, the evidence needed before thymosin alpha-1 could be considered in pregnancy would include:

• Completed GLP (Good Laboratory Practice) embryo-fetal developmental toxicity studies in at least two mammalian species, as required by ICH S5(R3) guidelines
• A prospective observational cohort of inadvertent first-trimester exposures with at least 100 to 200 documented pregnancies and reported outcomes
• Pharmacokinetic data on placental transfer across the first trimester
• Milk-transfer data from a lactation pharmacokinetic study

None of these exist in the published literature as of January 2025. Women have been under-represented in immunology and peptide trials, and reproductive-age exclusions have compounded that gap. The absence of data is a systemic failure of research design, not a green light for clinical use.

Thymosin alpha-1 across the female reproductive life span (outside pregnancy)

Outside of the pregnant and lactating state, thymosin alpha-1 has been studied in mixed-sex adult populations with the conditions below. Women-specific data are limited.

Reproductive years (non-pregnant)

The multicenter hepatitis B trial published in Hepatology enrolled both men and women, but sex-disaggregated outcomes were not reported. The dose used was 1.6 mg subcutaneously twice weekly for 6 months. No menstrual cycle effects, ovulatory effects, or hormonal interactions were characterized in that study.

Perimenopause and menopause

The perimenopausal immune shift, which involves declining estrogen and associated changes in T-cell function, has not been studied in the context of thymosin alpha-1 use. Estrogen withdrawal is associated with increased inflammatory cytokine production, and thymosin alpha-1's Th1-promoting properties could theoretically compound that shift. This is speculative, but it is the honest characterization of what is and is not known.

Autoimmune thyroid disease

Hashimoto thyroiditis, which affects approximately 1 in 10 women and is the leading cause of hypothyroidism in iodine-sufficient countries, involves a dysregulated Th1-dominant immune attack on thyroid tissue. Some integrative providers have used thymosin alpha-1 with the goal of recalibrating this immune excess, but no peer-reviewed randomized trial in Hashimoto patients has been published. Prescribing decisions in this context rely entirely on extrapolated immunological rationale, not direct evidence.

Clinical bottom line

Thymosin alpha-1 (thymalfasin) has no published human safety data for use during the first trimester, any trimester, or the breastfeeding period. The peptide's pharmacological mechanism of promoting Th1 immunity raises a specific biological concern during early pregnancy, a period when Th1 dominance is associated with implantation failure and early pregnancy loss. Women of reproductive age using this peptide should use reliable contraception unless actively trying to conceive, in which case the peptide should be stopped before conception attempts begin. If a pregnancy is discovered during use, stop the peptide, inform your OB and prescribing provider immediately, and consider reporting the exposure to FDA MedWatch.